Ivonescimab continues to draw strong attention following new clinical data presented at ESMO 2026. Oncology experts are weighing in on its expanding potential beyond non-small cell lung cancer (NSCLC) into biliary tract cancer (BTC).
Yakup Ergün, Medical Oncologist at Bower Hospital:
“Ivonescimab has now demonstrated its efficacy in multiple clinical trials. As physicians, we cannot afford to judge a treatment by its country of origin. We must focus on the scientific evidence and make this treatment available to eligible patients as soon as possible!”
Amol Akhade, Senior Consultant at Fortis Hospitals Mumbai:
“Is this going to be story for ESMO 2026 day 3? One thing is for sure, you may love it or you may not love it but you can not ignore it -ivonescimab. After NSCLC, it is BTC.”
You can also read:
HARMONi-GI1 at ESMO 2026: Ivonescimab Plus Chemotherapy in Advanced Biliary Tract Cancer
